Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 18/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.72 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.72 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.72 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.72 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6382260 | 1.00 | ADORA1 (0.72) | ADORA1ADORA3ADORA2AADORA2BSLC28A1 | |
| SCHEMBL5506309 | 0.94 | ADORA1 (0.64) | ADORA1ADORA3ADORA2AADORA2BSLC28A1 | |
| SCHEMBL6257614 | 0.94 | ADORA2A (0.69) | ADORA1ADORA3ADORA2AADORA2BSLC28A1 | |
| SCHEMBL6259026 | 0.90 | AHCY (0.65) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 | |
| SCHEMBL6266706 | 0.90 | AHCY (0.65) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 | |
| SCHEMBL5507638 | 0.88 | ADORA2A (0.67) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 | |
| SCHEMBL5507634 | 0.88 | ADORA2A (0.67) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 | |
| SCHEMBL5504529 | 0.88 | ADORA2A (0.70) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 | |
| SCHEMBL5992981 | 0.88 | ADORA2A (0.67) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 | |
| SCHEMBL16039098 | 0.87 | ADORA1 (0.77) | ADORA1ADORA3ADORA2AADORA2BSLC28A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060135467-A1 | Partial and full agonists of A1 adenosine receptors | ZABLOCKI JEFF | 2006-06-22 | — | — | US | claimed |
| US-20040043960-A1 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. | 2004-03-04 | — | — | US | claimed |
| EP-1537133-B1 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS | CV THERAPEUTICS INC (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060135467-A1 | Partial and full agonists of A1 adenosine receptors | ZABLOCKI JEFF | 2006-06-22 | — | — | US | disclosed |
| US-7022681-B2 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20040043960-A1 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135467-A1 | Partial and full agonists of A1 adenosine receptors | ADORA1, ADORA2A, ADORA3 | ADORA1 1/4885ADORA3 3/4885ADORA2A 2/4885 |
| US-20040043960-A1 | Partial and full agonists of A1 adenosine receptors | ADORA1, ADORA2A, ADORA3 | ADORA1 1/4885ADORA3 3/4885ADORA2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.